Journal of Endocrinological Investigation

, Volume 35, Issue 1, pp 87–89 | Cite as

For what reasons should metformin be used in the management of polycystic ovary syndrome?

  • P. MoghettiEmail author


Metformin polycystic ovary syndrome 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003: CD003053.Google Scholar
  2. 2.
    Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2010: CD003053.Google Scholar
  3. 3.
    Legro RS, Barnhart HX, Schlaff WD, et al; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007, 356: 551–66.PubMedCrossRefGoogle Scholar
  4. 4.
    Rausch ME, Legro RS, Barnhart HX, et al; Reproductive Medicine Network. Predictors of pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009, 94: 3458–66.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008, 23: 462–77; and Fertil Steril 2008, 89: 505–22.CrossRefGoogle Scholar
  6. 6.
    Vause TD, Cheung AP, Sierra S, et al; Society of Obstetricians and Gynecologists of Canada. Ovulation induction in polycystic ovary syndrome. J Obstet Gynaecol Can 2010, 32: 495–502; and Int J Gynaecol Obstet 2010, 111: 95–100.PubMedGoogle Scholar
  7. 7.
    Moll E, Korevaar JC, Bossuyt PM, van der Veen F. Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? Hum Reprod 2008, 23: 1830–4.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AEPCOS) Society. J Clin Endocrinol Metab 2010, 95: 2038–49.PubMedCrossRefGoogle Scholar
  9. 9.
    Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346: 393–403.PubMedCrossRefGoogle Scholar
  10. 10.
    Orchard TJ, Temprosa M, Goldberg R, et al; Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005, 142: 611–9.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000, 85: 139–46.PubMedGoogle Scholar
  12. 12.
    Kassi E, Diamanti-Kandarakis E. The effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome. J Endocrinol Invest 2008, 31: 1124–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2011, Nov 6 [Epub ahead of print]; doi: 10.1093/humupd/dmr042Google Scholar
  14. 14.
    Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011: CD007506.Google Scholar
  15. 15.
    Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32: 193–203; and Diabetologia 2009, 52: 17–30.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2012

Authors and Affiliations

  1. 1.Endocrinology and Metabolism, Department of MedicineUniversity of VeronaVeronaItaly
  2. 2.Unit of Endocrinology and Metabolic DiseasesAzienda Ospedaliera Universitaria Integrata VeronaVeronaItaly

Personalised recommendations